Trevi Therapeutics, Inc. Stock Split Ratio
Trevi Therapeutics, Inc. (TRVI) reported Stock Split Ratio of 100.00% for the 3-month period ending 2019-03-31, per its 10-K filed 2021-03-25.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2021-03-25
- Trevi Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2019-03-31 was 100.00%.
- Trevi Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2018 was 100.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|
| 2019-03-31 | 100.00% 10-K · filed 2021-03-25 | |
| 2018-12-31 | 100.00% 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |